ProShare Advisors LLC Has $423,000 Holdings in Adaptive Biotechnologies Corporation $ADPT

ProShare Advisors LLC boosted its stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 14.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 36,319 shares of the company’s stock after purchasing an additional 4,617 shares during the quarter. ProShare Advisors LLC’s holdings in Adaptive Biotechnologies were worth $423,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Verdence Capital Advisors LLC grew its position in shares of Adaptive Biotechnologies by 6.8% during the 2nd quarter. Verdence Capital Advisors LLC now owns 22,315 shares of the company’s stock worth $260,000 after buying an additional 1,426 shares during the period. Fox Run Management L.L.C. boosted its stake in Adaptive Biotechnologies by 8.2% during the 1st quarter. Fox Run Management L.L.C. now owns 21,565 shares of the company’s stock worth $160,000 after acquiring an additional 1,631 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in Adaptive Biotechnologies by 9.9% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 32,038 shares of the company’s stock valued at $373,000 after purchasing an additional 2,880 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Adaptive Biotechnologies by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after purchasing an additional 2,914 shares in the last quarter. Finally, Savant Capital LLC raised its holdings in Adaptive Biotechnologies by 15.4% in the second quarter. Savant Capital LLC now owns 39,665 shares of the company’s stock worth $462,000 after purchasing an additional 5,305 shares during the period. Institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Price Performance

Shares of Adaptive Biotechnologies stock opened at $16.32 on Friday. The firm has a market cap of $2.49 billion, a price-to-earnings ratio of -19.90 and a beta of 2.09. The stock’s 50-day moving average is $15.17 and its 200-day moving average is $12.47. Adaptive Biotechnologies Corporation has a one year low of $4.27 and a one year high of $17.89.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Adaptive Biotechnologies had a negative return on equity of 60.93% and a negative net margin of 59.07%.The business had revenue of $93.97 million for the quarter, compared to analyst estimates of $58.76 million. During the same quarter last year, the firm earned ($0.22) EPS. Adaptive Biotechnologies’s revenue for the quarter was up 102.4% compared to the same quarter last year. On average, equities analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ADPT shares. Morgan Stanley boosted their price target on shares of Adaptive Biotechnologies from $11.00 to $16.00 and gave the company an “equal weight” rating in a report on Tuesday, November 11th. Guggenheim initiated coverage on Adaptive Biotechnologies in a research note on Tuesday, September 30th. They issued a “buy” rating and a $20.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, October 8th. BTIG Research lifted their price objective on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Finally, Piper Sandler boosted their price objective on Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday, October 15th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Adaptive Biotechnologies has an average rating of “Moderate Buy” and an average price target of $16.56.

Insider Buying and Selling

In other Adaptive Biotechnologies news, CEO Chad M. Robins sold 1,867 shares of Adaptive Biotechnologies stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $15.00, for a total value of $28,005.00. Following the sale, the chief executive officer directly owned 2,869,975 shares in the company, valued at approximately $43,049,625. The trade was a 0.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Harlan S. Robins sold 10,000 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $14.82, for a total transaction of $148,200.00. Following the sale, the insider directly owned 1,269,524 shares in the company, valued at $18,814,345.68. This trade represents a 0.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 99,503 shares of company stock worth $1,466,724 over the last quarter. 6.40% of the stock is owned by corporate insiders.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.